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Abstract
The visualization of abnormal parathyroid glands is difficult due to their variations 
in number and localization. Noninvasive parathyroid imaging studies include 99mTc-
sestamibi scintigraphy, ultrasonography, computed tomography scanning, magnetic 
resonance imaging, and positron emission tomography. There is a general consensus 
that the most sensitive and specific imaging modality, especially when it is combined 
with single-photon emission CT is the scintigraphy with 99mTc-sestamibi or 99mTc-
tetrofosmin. 99mTc-sestamibi scintigraphy significantly increases the role of preopera-
tive scintigraphy in patients with hyperparathyroidism and allows unilateral surgical 
approach with minimally invasive parathyroidectomy to be used. Generally, three 
protocols with the use of two radiopharmaceuticals, 99mTc-sestamibi or 99mTc-tetro-
fosmin, are most widely applied: single-phase dual-isotope subtraction, dual-phase 
single-isotope and combination of both. Each one of them has specific advantages and 
disadvantages. While single parathyroid adenomas are localized with greater precision, 
hyperfunctioning parathyroid hyperplastic cells represent a real challenge to the imag-
ing modalities. Several factors can influence the radionuclide uptake in pathologically 
changed parathyroid cells, like the size, the level of their functional activity, the quan-
tity of oxyphilic cells, mitochondria, P glycoprotein and other MDR gene products.
Keywords: parthyroid scintigraphy, SPECT, 99mTc-sestamibi, 99mTc-tetrofosmin, 
99mTc pertechnetate
1. Introduction
Noninvasive parathyroid imaging studies include technetium (99mTc) ses-
tamibi scintigraphy, ultrasonography (US), computed tomography (CT) scan-
ning, magnetic resonance imaging (MRI) and positron emission tomography 
(PET). Parathyroid glands need to be examined in case of a diagnosed hyper-
parathyroidism as a part of preoperative localization of the abnormal glands. 
Hyperparathyroidism is characterized by elevated parathyroid hormone (PTH) 
levels in the blood. Due to the underlying cause, it can be divided into primary 
and secondary. The primary hyperparathyroidism (PHPT) is due to excessive 
production of PTH from one or more abnormal parathyroid glands. Secondary 
hyperparathyroidism (SHPT) is a result of hypocalcemia caused by other concomi-
tant diseases (end stage kidney renal disease, etc.). In SHPT usually more than one 
parathyroid glands are affected. Considered rare disease in the past, the incidence 
of PHPT has changed dramatically during the last 30 years with the introduction 
of routine calcium measurements in clinical practice, and is now considered to be 
approximately 42 per 100,000 persons. Women are affected more frequently than 
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men, in a ratio of approximately 3:1. PHPT occurs predominantly in individuals 
in their middle years with a peak incidence between ages 50 and 60 years and can 
reach 4 cases per 1000 persons in women after their 60s. At the time of diagnosis, 
most patients with PHPT do not have classic symptoms like osteitis fibrosa cys-
tica, nephrocalcinosis, nephrolithiasis or other signs associated with the disease. 
Symptomatic PHPT is now exception rather than the rule, with more than three-
fourths of patients having no symptoms making detected changes of the blood 
values of calcium, phosphorus and parathyroid hormone (PTH) to be the only 
reason for diagnosis [1, 2]. By far, the most common lesion found in patients with 
PHPT is the solitary parathyroid adenoma, occurring in 85–90% of patients, while 
in the rest 10–15% primary hyperplasia of the parathyroid glands is present [3]. 
In the past the standard surgical approach for PHPT was the bilateral four-gland 
parathyroid exploration with the removal of each gland which showed changes 
macroscopically. While in most of the patients with PHPT only one parathyroid 
gland is being affected, the above mentioned surgical approach is inappropriate 
in all cases. Unilateral approaches are appealing in a disease in which only a single 
gland is involved. So nowadays, the currently most widely used surgical approach 
is the minimally invasive parathyroidectomy which is connected with less post-
surgical complications and shortens the time of operation [4]. To be successful 
this procedure needs to rely on a precise preoperative localization of the abnormal 
parathyroid glands. That is, why preoperative parathyroid imaging gained so large 
importance. The rationale for locating abnormal parathyroid glands prior to surgery 
is that they can be notoriously unpredictable in their location.
2. Anatomy of the parathyroid glands
Parathyroid glands differ in shape and size. Typically four glands are present and 
are located adjacent to the dorsal surface of the thyroid lobes-two upper and two 
lower pairs. Normal glands tend to be flat and oval and normal measurements are 
3 × 5 × 7 mm [5]. The combined weight of all parathyroid glans is 90–130 mg and 
the superior glands are smaller than the inferior [6, 7]. Autopsy series demonstrate 
that four glands are found in 91% in subjects, five glands in 4%, and three glands 
in 5% [8]. Approximately 5% of humans have supernumerary (more than four) 
parathyroid glands [9]. Supernumerary glands are most commonly found within 
the thymus. Although gland distribution may deviate widely, the superior parathy-
roid glands, originating from the fourth pharyngeal pouch, are commonly found 
along the posterior surface of the upper two-thirds of the thyroid gland (92%). 
The inferior parathyroid glands have a more variable distribution than the superior 
ones. They originate from the third pharyngeal pouch together with the thymus. 
They migrate caudally until they reach the lower pole of the thyroid gland and 17% 
of them touch the inferior border of the thyroid gland, 26% are within the supe-
rior horn of the thymus, and 2% are in the mediastinal thymus [10]. The variable 
anatomic distribution makes the inferior glands more difficult to locate than the 
superior ones. Histologically parathyroid glands are made of chief, oxyphillic and 
transient oxyphillic cells mixed with fat tissue. Chief cells produce PTH. The oxy-
phillic cells which are rich of mitochondria are with poorly defined function [11].
3. Noninvasive parathyroid imaging
The normal parathyroid glands cannot be visualized. The lack of the perfect 
imaging method for precise localization of parathyroid adenomas had led to search 
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for an alternative imaging techniques. Ultrasonography (US) is one of the most 
widely used procedures. Because of the great anatomic variations of the parathyroid 
glands, their small sizes, the presence of more than one abnormal gland and the 
higher frequency of concomitant morphological changes of the thyroid gland, US 
proved to be specific but with low sensitivity. The success of US is highly operator 
dependent [12]. Rapid spiral thin-slice CT scanning of the neck and mediastinum 
with evaluation of axial, coronal and sagittal views can add much to the search for 
elusive parathyroid tissue [13]. MRI can also identify abnormal parathyroid tissue, 
but it is time consuming and expensive. It is also less sensitive than other modalities. 
It can nonetheless be useful when the search with the other noninvasive approaches 
has been unsuccessful. PET/CT can be used, but like MRI, it is expensive and does 
not have the kind of experiential basis that make it attractive. There are limiting 
data for using PET/CT in parathyroid imaging. PET with 18F-fluorodeoxyglucose 
(18F-FDG) was used with varying success. One study showed that 18F-FDG РЕТ was 
more sensitive but less specific than 99mTc-sestamibi SPECT [14]. Others reported 
very low sensitivity for detecting abnormal parathyroid glands [15]. Using РЕТ with 
11C-methionine in parathyroid examination has been studied in some patients but 
because of the very short half-life of 11C-methionine, only 20 min its use is limited 
only to nuclear medicine centers located near to a cyclotron. There is a general 
consensus that the most sensitive and specific imaging modality, especially when 
it is combined with single-photon emission CT (SPECT) is the scintigraphy with 
99mTc-sestamibi or 99mTc-tetrofosmin.
4. Parathyrod scintigraphy
Historically, the success of scintigraphy had been compromised by the failure 
of finding a pharmaceutical agent with specific topic accumulation in parathyroid 
glands and their close proximity to the thyroid gland. That is why to find a reli-
able method to differentiate both glands on scintigraphy was crucial. This was 
first achieved by a combined use of two radionuclides with different uptake in the 
thyroid and parathyroid cells. The latter allowed to perform a subtraction of the 
obtained images of both glands and to visualize only the abnormal parathyroid 
gland, but this proved to be time consuming and with greate radiation exposure 
to the patients. The first widely used radionuclide for detecting hyperfunctioning 
parathyroid glands during the 80s was 201Thallium chloride (201Tl). 201Tl chloride 
accumulates equally in thyroid and parathyroid cells. To make differentiation 
possible, its application was followed by an injection of 99mTc pertechnetate, with 
predominant thyroid uptake. Then 99mTc pertechnetate thyroid images were digi-
tally subtracted from the images obtained with 201Tl chloride to allow visualization 
only of the parathyroid glands [16].
Introduced in clinical practice by Coakley et al. [17], the 99mTc-sestamibi 
scintigraphy significantly increased the role of preoperative scintigraphy in patients 
with hyperparathyroidism. Firstly used as a cardiotropic agent this radionuclide 
showed increased accumulation in a variety of benign and malignant tumors. 
99mTc-sestamibi consists of lipophilic cationic molecules. After being intravenously 
injected these molecules distribute throughout the body accordingly to the local 
blood supply and by passive diffusion through cell’s membrane accumulate intra-
cellularly into the mitochondria [18, 19]. Normally 99mTc-sestamibi distributes in 
parotid and submandibular salivary glands, thyroid gland, the heart and the liver, 
but not in normal parathyroid glands. Visualization of parathyroid adenomas 
and hyperplastic parathyroid glands depends on the presence of oxyphillic cells, 
which are rich of mitochondria. The cells of parathyroid adenomas have plenty of 
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mitochondria [20], while the normal parathyroid cells do not [21]. The highest rates 
of uptake of 99mTc-sestamibi are seen in the solitary adenomas of the parathyroid 
glands [22]. Not only the amount of intracellular mitochondria is important but also 
the quantity of oxyphillic cells in the tumors. If the percentage of oxyphillic cells 
exceeded 25%, accumulation of 99mTc-sestamibi was observed in 78% of parathy-
roid adenomas. Also false negative results are possible if the oxyphillic cells do not 
content sufficient amount of mitochondria [23]. Accumulation of 99mTc-sestamibi 
into the cells also can be influenced by their metabolic activity, the weight and the 
size of the tumor. This new radionuclide rapidly replaced 201Tl chloride because it 
showed better quality of the images and higher sensitivity for detecting abnormal 
parathyroid glands, with less radiation exposure [24].
99mTc-tetrofosmin another myocardial perfusion agent was also used for visual-
izing parathyroid glands in scintigraphy, but the data for its use so far are limited. 
99mTc-tetrofosmin shows some similarities with 99mTc-sestamibi although the way of 
accumulation is different and it is retained mainly in the cytosol rather than in the 
mitochondria of the target cells. When used for parathyroid scintigraphy 99mTc-tet-
rofosmin shows slower washout from the thyroid gland, which makes it unsuitable 
for single-isotope dual-phase scintigraphy [25]. Nevertheless its sensitivity increases 
when used in combination with SPECT. Several studies [26, 27] of the diagnostic 
value of 99mTc-tetrofosmin scintigraphy for topic localization of the hyperfunction-
ing parathyroid glands in patients with PHPT, showed that this method was useful 
for the clinical practice and that the accumulation of 99mTc-tetrofosmin depends on 
the weight of the tumor and the level of PTH.
4.1 Protocols for nuclear medicine examination of parathyroid glands
Generally three protocols are most widely used: single-phase dual-isotope 
subtraction, dual-phase single-isotope and combination of both [28].
In single-phase dual-isotope modality two types of radiopharmaceuticals with 
different organ uptake are used. One isotope (99mTc-sestamibi or 99mTc-tetrofosmin) 
with equal thyroid and parathyroid glands accumulation and another (123I or 
99mTc-pertechnetate) with predominant uptake in the thyroid gland are applied 
consecutively. The obtained images are digitally subtracted and if there is a residual 
radionuclide accumulation on the subtracted images a hyperfunctioning parathy-
roid gland can be suspected [28]. Disadvantages of this method are the use of two 
radionuclides, the necessity of full collaboration from the patient’s side to stay calm 
and motionless during the examination and the need of very precise positioning of 
the patient. In addition there is an increase possibility for the presence of artifacts 
on the subtracted images [29, 30].
The rationale of the single-isotope protocol is based upon the different wash-
out periods of the radionuclide from the thyroid and parathyroid glands. In this 
method, after an injection of a single radionuclide, early (at 10–15 min) and late  
(at 1.5–3 h) images are obtained [28].
There are a very few studies directly comparing the results from single-isotope 
dual-phase modality with single-phase dual-isotope subtractional scintigraphy and 
the results are inconclusive [31, 32]. So far there is no clear confirmed advantages of 
one type over another.
4.1.1 Preparation of the patient
No preliminary preparation of the patients before performing single isotope 
dual-phase scintigraphy is necessary. In subtractional modality some preliminary 
conditions should be followed such as: discontinuation of Levothyroxine or Iodine 
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containing drugs minimum 20 days before the examination. A case history of every 
patient about the duration of the disease, any concomitant diseases and medica-
tions, especially drugs that could possibly interfere with the calcium-phosphate 
homeostasis, and family history should be taken.
4.1.2 Radiopharmaceuticals
99mTc-sestamibi and 99mTc-tetrofosmin: they are applied intravenously from 740 
to 1110 MBq (20–30 mCi).
99mTc-pertechnetate has a half-life of 6 h and possesses energy of 140 keV. It is 
used for visualization of the thyroid gland because it accumulates in a function-
ing thyroid cells. Intravenously 99mTc-pertechnetate is applied form 74–350 MBq 
(2–10 mCi).
4.2  Single-isotope dual-phase scintigraphy with 99mTc-sestamibi and 
99mTc-tetrofosmin
4.2.1 Single-isotope dual-phase scintigraphy with 99mTc-sestamibi
99mTc-sestamibi accumulates in the thyroid and parathyroid glands, but the 
washout time from both glands differs, showing faster disappearing from the 
thyroid and retention in parathyroid cells. This allows successful visualization of 
pathologically changed parathyroid glands on the obtained later images—1.5–2 h 
after the injection of the radionuclide. This different retention time in both glands 
may be related to some down-regulation of the P-glycoprotein system in para-
thyroid adenomas, which delays washout of the nuclide [33]. Just the opposite, in 
parathyroid hyperplasia these so-called multidrug-related resistance molecules can 
be upregulated and can cause faster washout of 99mTc-sestamibi and lead to false 
negative results [34, 35].
To avoid this disadvantage and to improve sensitivity and specificity, the use 
of single-isotope dual phase (early and late) scintigraphy, based upon the sugges-
tion that 99mTc-sestamibi is washed out faster from the thyroid gland than from 
the hyperfunctioning parathyroid cells, is recommended [36]. This single-isotope 
dual phase scintigraphy gained popularity due to its convenience. The fact that 
99mTc-sestamibi can also be accumulated in solitary thyroid nodules diminishes the 
specificity of this procedure, especially in areas with higher incidence of nodular 
goiter [37, 38]. Some parathyroid adenomas also show rapid washout of 99mTc-
sestamibi and make their visualization difficult by this procedure [39]. This led to 
an introduction of a modified protocol for subtractional scintigraphy by adding a 
second radionuclide with a preferential accumulation in the thyroid tissue.
99mTc-sestamibi scintigraphy is generally regarded to be the most sensitive 
and specific imaging modality especially when it is combined with other imag-
ing procedures. The combination of US examination with dual-isotope 99mTc 
pertechnetate/99mTc-sestamibi scintigraphy for preoperative localization of 
parathyroid adenomas leads to visualizing of the parathyroid adenomas in 95.2% 
of the cases (20 patients out of 21). Reaching such high diagnostic precision allows 
to minimize the extent of the surgical procedure and gives way to apply routinely 
and successfully minimally invasive parathyroidectomy only of the pathologically 
changed glands [40, 41].
Comparing different imaging methods,99mTc-sestamibi scintigraphy has higher 
sensitivity and specificity than US and CT in discovering adenomas of the parathy-
roid glands. With regards to the hyperplasia of the parathyroid glands 99mTc-sesta-
mibi scintigraphy shows to be of less value [42, 43]. Hyperplastic parathyroid glands 
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are visualized in 10–62.5% of the cases [44, 45]. In multiple endocrine neoplasia 
syndrome (MEN), where hyperplasia of the parathyroid glands is common, only 55% 
of the abnormal glands are seen on 99mTc-sestamibi scintigraphy [42, 46, 47]. 99mTc-
sestamibi scintigraphy shows to be highly effective in discovering ectopic hyperfunc-
tioning parathyroid glands, which in some studies, are observed in approximately 
20% of the cases with PHPT and represent a diagnostic and therapeutic challenge 
[48]. Visualizing small parathyroid adenomas represents a specific problem. One 
study showed, that in surgically removed adenomas weighted less than 0.5 g, preop-
erative US was negative, but 99mTc-sestamibi scintigraphy discovered adenomas in 
87% of cases and the combination with SPECT increased sensitivity to 95% [21].
In patients with SHPT, seems to have a direct correlation between 99mTc-
sestamibi uptake with the blood level of parathyroid hormone and the phase of the 
cells’ cycles [49]. The lowest level of accumulation corresponds to G(0) phase and 
the highest to phase G(2) + S. No such correlation with the weight of the glands is 
found [49]. The fixation of the radionuclide depends on the functional status of the 
tissues, i.e., increased accumulation accompanies the cells’ active growing phase or 
is directly connected to the state of autonomy of the parathyroid cells [46].
The reason why not all pathologically changed parathyroid glands accumulate 
radionuclide remains unclear. This may be due to the different degree of activity 
and proliferation of the cells of the parathyroid adenomas. It was suggested that 
there is a relationship between nuclide accumulation and the degree of autonomy 
of the cells of the adenoma, i.e., the loss of the suppressive effect of calcium upon 
the secretion of the parathyroid hormone. The cells of the parathyroid adenomas 
and these of the hyperplastic glands show higher threshold for calcium suppres-
sion or have no threshold at all in comparison with the normal parathyroid cells. 
Due to this fact, these cells secrete more PTH for any given blood calcium level, 
show higher metabolic rate and capability to accumulate more 99mTc-sestamibi. 
Hyperplastic parathyroid glands are to some extent with preserved functional 
regulation, respond to the normal suppressive stimuluses, have lower metabolic rate 
and accumulate less of the radionuclide.
Due to its higher affinity to the parathyroid adenomas, 99mTc-sestamibi scintig-
raphy was used in cases of relapse of the hyperparathyroidism after parathyroidec-
tomy or after autotransplantation of parathyroid glands.
Nowadays, there are several imaging methods for discovering hyperplastic 
parathyroid glands. The results so far are inconclusive. The dual-phase 99mTc-
sestamibi scintigraphy in preoperative localization of the hyperplastic parathyroid 
glands in patients with profound secondary hyperparathyroidism do not show high 
sensitivity, but is of help to discriminate between patients with nodular and diffuse 
hyperplasia [50].
The role of 99mTc-sestamibi scintigraphy in patients with end-stage renal disease 
and secondary hyperparathyroidism is still unclear. The uptake of 99mTc-sestamibi 
can be suppressed by the use of calcitriol in these patients. In one study [51] 99mTc-
sestamibi scintigraphy managed to visualize 1 or more (maximum 3) parathyroid 
glands in most, but not in all patients on hemodialysis with PHT levels above 
600 pg/ml. Performing suppressive test with calcitriol (2 mg of calcitriol applied i.v. 
after each hemodialysis for two consecutive weeks) showed suppression of 99mTc-
sestamibi uptake at least in one parathyroid gland in 57% of the cases and full sup-
pression in all glands in 36%. The basal level of PHT or its lowering after this test 
showed to be of no predictive value for the suppression of 99mTc-sestamibi uptake in 
the parathyroid glands. Because of its lower sensitivity, the 99mTc-sestamibi scintig-
raphy was found to be of limited value in preoperative evaluation in uremic patients 
with secondary hyperparathyroidism, but its significance grew up in localizing 
hyperfunctioning glands left after the first operation [51].
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Single-isotope dual phase 99mTc-sestamibi scintigraphy is easily performed, and 
needs only application of 99mTc-sestamibi. After injection of the radiopharmaceutical, 
early (10–15 min), and late planar (1,5–3 h) images are obtained (Figures 1 and 2).
Figure 1. 
Single-isotope dual-phase scintigraphy with 99mTc-sestamibi. The late image (120 min) shows a focus of 
a residual activity (arrow), caudally of the right thyroid lobe consistent with adenoma of the right lower 
parathyroid gland.
Figure 2. 
Single-isotope dual-phase scintigraphy with 99mTc-sestamibi. On the early images (20 min) relatively diffuse 
uptake in the area of the thyroid gland and a focus of increased accumulation of the radionuclide (thin 
arrow), caudally of the left thyroid lobe are seen. On the late phase images (120 min) only a focus of a residual 
activity (thick arrow), caudally of the left thyroid lobe is visualized-suggesting adenoma of the lower left 
parathyroid gland.
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In some cases, the obtained early and late images show no signs of abnormal 
accumulation of radionuclide, but when combined with SPECT, than adenomas 
located at the back of the thyroid gland become visible (Figure 3a and b).
So, the combination of a single-isotope dual-phase scintigraphy with 99mTc-
sestamibi with SPECT can be of great help.
During many years in the past, two-dimensional images have been obtained, mainly 
AP-images, and rarely this was combined with lateral and oblique images [52, 53].
SPECT has gained more importance, because it gives three-dimensional images. 
There are accumulating data from the literature, that it improves sensitivity for 
discovering and localizing the hyperfunctioning parathyroid glands [54, 55]. The 
main reason for this is the improved contrast resolution of SPECT (Figure 4).
4.2.2 Single-isotope dual-phase scintigraphy with 99mTc-tetrofosmin
99mTc-tetrofosmin, another myocardial perfusion agent, is also used for para-
thyroid scintigraphy, but there are limited data in the literature for its use. Several 
Figure 3. 
(a) Single-isotope dual-phase scintigraphy with 99mTc-sestamibi. Early planar images show diffuse uptake 
in the thyroid gland. Late planar images show no sign of a focus of residual activity in the neck area or 
mediastinum. (b) (The same patient) 99mTc-sestamibi SPECT images show an area of a residual activity, 
located dorsally and caudally of the left thyroid lobe (arrows) suspicious for a parathyroid adenoma.
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studies [26, 27] assess the diagnostic value of 99mTc-tetrofosmin scintigraphy for 
topic localization of the hyperfunctioning parathyroid glands in patients with 
PHPT. They show that this method was useful for the clinical practice and that 
the accumulation of 99mTc-tetrofosmin depended on the weight of the tumor and 
the level of PTH. The early images (15th min) prove to be better than the late ones 
(120th min). 99mTc-tetrofosmin is washed out more slowly from the thyroid gland 
than 99mTc-sestamibi but both radionuclides give better results in comparison with 
99mTc-pertechnetate/201Tl-substractional technique [56]. 99mTc-tetrofosmin looks 
promising alternative of 99mTc-sestamibi with similar properties and capabilities of 
localizing parathyroid adenomas.
Dual-isotope substractional scintigraphy with 99mTc-tetrofosmin/99mTc-pertech-
netate and SPECT represent highly sensitive method for localization of parathyroid 
adenomas and their combination can further improve the diagnostic precision [57]. 
99mTc-tetrofosmin, like 99mTc-sestamibi is not perfect for localization of hyperplas-
tic parathyroid glands in patients with SHPT, because of its lower sensitivity [56]. 
99mTc-tetrofosmin has some similarities with 99mTc-sestamibi, but its mechanism 
of accumulation in the cells is different. In contrast with 99mTc-sestamibi, which 
accumulation depends on mitochondria’s membrane potential, retention of 99mTc-
tetrofosmin depends mainly on cell’s membrane potential [25]. 99mTc-tetrofosmin, 
shows slower wash out from the thyroid on the late planar images (120 min). This 
leads to the necessity to obtain additional later planar images—between 150 and 
160 min. This slower wash out makes 99mTc-tetrofosmin to be unsuitable for per-
forming single-isotope, dual-phase scintigraphy [25]. To avoid misleading, because 
of prolonged retention of the radiopharmaceutical in the thyroid adenomas, an US 
examination should be performed, especially in iodine deficient areas [56].
Figure 5 is presented a single-isotope dual-phase scintigraphy with 99mTc-
tetrofosmin, combined with SPECT in a patient with PHPT.
In 99mTc-tetrofosmin scintigraphy early images at 20th min show better quality 
than the later ones at 120th min (Figure 6a–c).
Late planar images (120 min)—negative scan.
Figure 4. 
Early 99mTc-sestamibi SPECT images showing an area of radionuclide accumulation (arrows), located dorsally 
and caudally of the left thyroid lobe.
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In this case, early SPECT gives opportunity to visualize adenomas, which were 
not seen on the late planar images, which is probably due to the rapid wash out 
of the radiopharmaceutical from some adenomas, as well as to the small sizes of 
the adenomas. When combined with SPECT, dual-phase scintigraphy with 99mTc-
tetrofosmin can detect adenomas with rapid wash out of the radiopharmaceuticals.
Pearls/pitfalls:
a. The single isotope dual-phase scintigraphy with 99mTc-sestamibi or 99mTc-
tetrofosmin could miss parathyroid adenomas with rapid washout of the 
radionuclide. The combination with early SPECT improves sensitivity.
b. The single isotope dual-phase scintigraphy with 99mTc-tetrofosmin in patients 
with PHPT and SHPT is with less sensitivity and specificity, because of the 
Figure 5. 
(a) Early phase image (20 min) shows an intense uptake of the radionuclide at the lower part of the right 
thyroid lobe, which activity is still present on the late image (120 min) (arrows) and (b) (same patient) 
SPECT images showing an intense uptake dorsally and caudally of the right thyroid lob (arrow), suggestive for 
adenoma of the right lower parathyroid gland.
11
Parathyroid Scintigraphy
DOI: http://dx.doi.org/10.5772/intechopen.90341
poor quality of the obtained images and slower washout of the radionuclide 
from the thyroid gland.
c. SPECT combined with single-isotope scintigraphy and subtractional methods 
for visualization of hyperfunctioning parathyroid adenomas in patients with 
PHPT and SHPT is a reliable additional modality. It does not cause additional 
and unnecessary exposure of the patients to the gamma-rays and can increase 
sensitivity.
Figure 6. 
(a) Single-isotope dual-phase scintigraphy with 99mTc-tetrofosmin. Early planar images (20 min) are with 
better quality, (b) (same patient) single-isotope dual-phase scintigraphy with 99mTc-tetrofosmin and (c) 99mTc-
tetrofosmin SPECT images—an area (arroes) with high uptake located dorsally of the lower right lobe is seen, 
consistent with adenoma of the right lower parathyroid gland.
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4.3  Dual-isotope subtractional scintigraphy with: 99mTc-pertehnetat/99mTc 
sestamibi or 99mTc-pertehnetat/99mTc-tetrofosmin
4.3.1  Dual-isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc 
sestamibi
The rationale that stands behind dual-isotope subtractional scintigraphy with 
99mTc-pertehnetat/99mTc sestamibi, is that 99mTc-sestamibi accumulates in both, 
thyroid gland and hyperfunctioning parathyroid glands, while 99mTc-pertechnetate 
uptakes only in the thyroid. First thyroid specific radionuclide 99mTc-pertechnetate 
Figure 7. 
(а) Dual-isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc sestamibi. Upper image on the 
left-image of thyroid gland obtained with 99mTc-pertehnetat. Upper image on the right an image obtained with 
99mTc sestamibi (arrow). Lower image. Subtractional image showing a focus of a residual activity (arrow) 
in upper back part of the left thyroid lobe consistent with left parathyroid adenoma and (b) (same patient) 
dual-isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc sestamibi. Early SPECT images showing 
an area of intense uptake located dorsally and cranially of the left thyroid lobe.
13
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is injected and at 30th min images are obtained. Afterwards, while the patient is still 
under the detector, second radionuclide 99mTc sestamibi with dual accumulation is 
applied and a second set of images on the 20th min are obtained. Later images are 
subtracted digitally from the first set of images and if a focus of residual activity on 
the subtractional images is detected, a hyperfunctioning parathyroid gland is sup-
posed. The combination with early SPECT can improve sensitivity (Figure 7a and b).
The subtraction could be of help, when the patients had undergone surgery of 
the thyroid, but some thyroid parenchyma is still present. This method is important 
in the presence of more than one abnormal parathyroid gland.
Dual-isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc 
sestamibi combined with SPECT in a 51 years old man with MEN-type 1 
Figure 8. 
(а) Dual-isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc sestamibi. Subtractional image 
showing two areas of intense uptake consistent with two parathyroid adenomas and (b) SPECT images 
showing an area of intense uptake located dorsally and caudally of the right thyroid lobe.
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syndrome—pheochromocytoma, parathyroid adenoma and prolactinoma, who had 
previously undergone thyroid (subtotal thyroidectomy) and parathyroid (left upper 
parathyroid gland) surgery. Subtractional images (Figure 8a) and early SPECT 
images (Figure 8b) show two areas of intense uptake located below the remnants of 
the both thyroid lobes. SPECT images show that the lesion below the right thyroid 
lobe was located also adjacent to the back part of the right thyroid lobe.
In some cases, obtaining late images could also be of help. Combining dual-
isotope, 99mTc-pertehnetat/99mTc sestamibi, subtractional scintigraphy with SPECT, 
and also recording late planar images on the 120th min (late phase) would improve 
sensitivity (Figures 9 and 10).
Pearls/pitfalls
a. Dual isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc sestamibi 
or 99mTc-pertehnetat/99mTc-tetrofosmin allows visualization of abnormal para-
thyroid glands after subtraction is performed, even on the early obtained images. 
Figure 9. 
(а) Dual-isotope subtractional scintigraphy with 99mTc-pertehnetat/99mTc sestamibi. Subtractional image 
showing no residual activity in the areas of the neck and chest and (b) late planar images showing a residual 
activity (arrow) in the middle of the left thyroid lobe, consistent with left parathyroid adenoma.
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This helps to shorten the time of examination to 80–90 min and is of great use in 
the postsurgical follow up and when more than one abnormal gland is present.
b. Disadvantages of the subtractional scintigraphy with 99mTc-pertehnetat/99mTc 
sestamibi or 99mTc-pertehnetat/99mTc-tetrofosmin are: necessity of applying 
of two radionuclides, the need of very precise positioning of the patients in 
this dual phase method requiring full collaboration from patient’s side and the 
probability of the presence of artifacts in the obtained images.
Figure 10. 
(а) Dual-isotope subtractional method with 99mTc-pertehnetat/99mTc-tetrofosmin. The upper row: on the left 
image of the thyroid gland with 99mTc-pertehnetat and on the right image of the parathyroid gland with 99mTc-
tetrofosmin (arrow). The lower row shows subtractional image representing adenoma of left parathyroid gland 
and (b) dual-isotope subtractional method with 99mTc-pertehnetat/99mTc-tetrofosmin early SPECT images 
showing an area of hyper fixation, located caudally of the left thyroid lobe.
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Figure 11. 
Single-isotope, dual-phase scintigraphy with 99mTc-sestamibi in a patient with secondary hyperparathyroidism. 
The late phase (120 min) show a focus of residual activity (arrow)—consistent with parathyroid adenoma 
(probably tertiary hyperparathyroidism).
Figure 12. 
(а) Single-isotope, dual-phase scintigraphy with 99mTc-tetrofosmin in a patient with secondary 
hyperparathyroidism. Early (20 min) and late (120 min) images show no focus of a residual activity in 
the area of neck and mediastinum and (b) (same patient) early SPECT images showing an area of nuclide 
accumulation caudally of the left thyroid lobe, suspicious for parathyroid adenoma.
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4.4 Secondary hyperparathyroidism
Secondary hyperparathyroidism is characterized with hyperplasia of parathy-
roid glands, because it is caused by longstanding uncontrolled hypocalcemia, which 
leads to a profound overstimulation of a previously normal parathyroid glands. 
Over time this overstimulation causes hyperplasia and eventually adenomatous 
changes (tertiary hyperparathyroidism) of the parathyroid glands with PTH levels 
far more exceeding those observed in PHPT (Figure 11). Nevertheless, hyperplastic 
parathyroid glands usually show faster wash out of the radionuclides in comparison 
to solitary adenomas, which makes them more difficult to be visualized with scin-
tigraphy (Figure 12). Negative scans, may be associated with the possible suppres-
sion of the accumulation of radiopharmaceuticals in the parathyroid cells as a result 
of the concomitant calcitriol intake. The use of calcium channel blockers may affect 
the uptake of 99mTc-sestamibi by parathyroid cells and reduce the sensitivity of the 
method. A study found that negative scans are twice as likely in patients taking 
calcium antagonists than those who do not take these medications (OR2, 88.95% 
CI, 1.03–8.10, p 0.045) [58]. So, adding the poor general condition of the patients, 
pathologically changed parathyroid glands are more difficult to be localized in 
SHPT than in PHPT.
5. Conclusions
The visualization of abnormal parathyroid glands is difficult due to their 
variations in number and localization. Noninvasive parathyroid imaging studies 
include 99mTc-sestamibi scintigraphy, ultrasonography, computed tomography 
scanning, magnetic resonance imaging, and positron emission tomography. There 
is a general consensus that the most sensitive and specific imaging modality is the 
scintigraphy with 99mTc-sestamibi or 99mTc-tetrofosmin. 99mTc-sestamibi scin-
tigraphy significantly increases the role of preoperative scintigraphy in patients 
with hyperparathyroidism and allows unilateral surgical approach with minimally 
invasive parathyroidectomy to be used. Generally three protocols with the use of 
two radiopharmaceuticals, 99mTc-sestamibi or 99mTc-tetrofosmin, are most widely 
applied: single-phase dual-isotope subtraction, dual-phase single-isotope and 
combination of both. Each one of them has specific advantages and disadvantages. 
While, single parathyroid adenomas are localized with greater precision, hyper-
functioning parathyroid hyperplastic cells represent a real challenge to the imaging 
modalities.
Several factors can influence the radionuclide uptake in pathologically changed 
parathyroid cells:
a. biochemical factors
• Total calcium levels—higher preoperative calcium levels are more frequently 
seen in patients with positive scans.
• Parathyroid hormone levels.
• A significant correlation between radiopharmaceutical uptake and preopera-
tive levels of PTH is observed. As higher PTH is, as higher is the possibility 
for positive scans.
• Vitamin D levels.
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• Patents with vitamin D deficiency are more likely to have positive scans.
• Suboptimal levels of vitamin D, can stimulate the growth of the parathyroid 
adenomas independently from hypocalcemia and 1,25-dihydroxyvitamin 
D3 deficit can change the set-point of calcium suppressive effect upon PTH 
secretion [59].
• Calcium-channel blockers.
• The use of calcium-channel blockers can influence the uptake of the radio-
pharmaceutical in the parathyroid cells diminishing the sensitivity of the 
method.
b. biological factors
• Size—although considered to be very important, it is not the only determin-
ing factor.
• Type of cells of the parathyroid adenoma—because oxyphilic cells contain 
more mitochondria, they uptake radionuclides to a larger extent.
• P glycoprotein and MDR gene products.
Uptake of 99mТс-sestamibi and 99mТс-tetrofosmin in the cells of the parathyroid 
adenomas depends on the activity of the P glycoprotein coded by MDR gene, which 
is functioning as an ATP dependent efflux pump, protecting against accumulation of 
lipophilic cationic radiopharmaceuticals, including 99mТс-tetrofosmin [60]. The expres-
sion of P glycoprotein in the parathyroid adenomas appears to be important factor 
determining radiopharmaceutical uptake. In one study 71% (10 out of 14) of adenomas 
with high P glycoprotein membrane activity have shown negative scans, 70% (45 out of 
64) with negative P glycoprotein expression (р = 0.006) have shown positive scans [61].
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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